0000950170-23-050819.txt : 20230929 0000950170-23-050819.hdr.sgml : 20230929 20230929164650 ACCESSION NUMBER: 0000950170-23-050819 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230927 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230929 DATE AS OF CHANGE: 20230929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clearside Biomedical, Inc. CENTRAL INDEX KEY: 0001539029 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452437375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37783 FILM NUMBER: 231296353 BUSINESS ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 BUSINESS PHONE: 678-270-3631 MAIL ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 8-K 1 clsd-20230927.htm 8-K 8-K
false000153902900015390292023-09-272023-09-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2023

 

 

Clearside Biomedical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37783

45-2437375

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

900 North Point Parkway

Suite 200

 

Alpharetta, Georgia

 

30005

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 678 270-3631

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CLSD

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 27, 2023, Clearside Biomedical, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 25, 2024, to regain compliance with the rule referred to in this paragraph. To regain compliance, during this 180-day compliance period, the Company’s minimum bid price of listed securities must close at $1.00 per share or more for a minimum of 10 consecutive business days. The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market.

In the event that the Company does not regain compliance with the Nasdaq Listing Rules prior to the expiration of the 180-day compliance period, the Company may be eligible for additional time to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(ii) by transferring to the Nasdaq Capital Market. To qualify, the Company would need to submit a Transfer Application and a $5,000 application fee. In addition, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. In addition, the Company would need to provide written notice to Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. As part of its review process, the Nasdaq staff will make a determination of whether it believes the Company will be able to cure this deficiency. Should the Nasdaq staff conclude that the Company will not be able to cure the deficiency, or should the Company determine not to submit a Transfer Application or make the required representation, Nasdaq will provide notice that the Company’s shares of common stock will be subject to delisting.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s shares of common stock will be subject to delisting. At such time, the Company may appeal the delisting determination to a Hearings Panel.

The Company intends to actively monitor its minimum bid price of listed securities and, as appropriate, will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market or effecting a reverse stock split.

There can be no assurance that the Company will be successful in maintaining the listing of its common stock on the Nasdaq Global Market, or, if transferred, on the Nasdaq Capital Market. This could impair the liquidity and market price of its common stock. In addition, the delisting of its common stock from a national exchange could have a material adverse effect on the Company’s access to capital markets, and any limitation on market liquidity or reduction in the price of its common stock as a result of that delisting could adversely affect the Company’s ability to raise capital on terms acceptable to the Company, or at all.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 29, 2023

CLEARSIDE BIOMEDICAL, INC.

By:

/s/ Charles A. Deignan

Name:

Charles A. Deignan

Title:

Chief Financial Officer

 

 EX-101.LAB 2 clsd-20230927_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 3 clsd-20230927.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 clsd-20230927_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Sep. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 27, 2023
Entity Registrant Name Clearside Biomedical, Inc.
Entity Central Index Key 0001539029
Entity Emerging Growth Company false
Securities Act File Number 001-37783
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2437375
Entity Address, Address Line One 900 North Point Parkway
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Alpharetta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30005
City Area Code 678
Local Phone Number 270-3631
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CLSD
Security Exchange Name NASDAQ
XML 6 clsd-20230927_htm.xml IDEA: XBRL DOCUMENT 0001539029 2023-09-27 2023-09-27 false 0001539029 8-K 2023-09-27 Clearside Biomedical, Inc. DE 001-37783 45-2437375 900 North Point Parkway Suite 200 Alpharetta GA 30005 678 270-3631 false false false false Common Stock, par value $0.001 per share CLSD NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports clsd-20230927.htm clsd-20230927.xsd clsd-20230927_lab.xml clsd-20230927_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "clsd-20230927.htm": { "nsprefix": "clsd", "nsuri": "http://clearsidebio.com/20230927", "dts": { "inline": { "local": [ "clsd-20230927.htm" ] }, "schema": { "local": [ "clsd-20230927.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "clsd-20230927_lab.xml" ] }, "presentationLink": { "local": [ "clsd-20230927_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_8ee1aa1a-ce1c-4e56-845e-6f05ab097fbd", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20230927.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8ee1aa1a-ce1c-4e56-845e-6f05ab097fbd", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20230927.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://clearsidebio.com/20230927/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-23-050819-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-050819-xbrl.zip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